Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic
  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Week in Review: Hansoh Signs $456 Million Deal for siRNA Products

Deals and Financings   Hansoh Pharma of  Shanghai  announced a $456 million agreement to develop siRNA products from  South Korea 's OliX Pharma in Greater China; Abbisko, a  Shanghai  biopharma, completed a $226 million IPO in  Hong Kong  to support its small molecule therapies for cancer; Shanghai BioNova Pharma optioned  China  rights to a CD74 mAb for hematologic cancers from Sutro Biopharma in a $204 million agreement; Sciwind Biosciences, a  Hangzhou  biopharma focused on metabolic disease, closed a $70 million Series C funding for GLP-1 receptor agonist candidates; Chance Pharma of Hangzhou, an inhalation therapy company, completed a $30 million Series C financing led by Lapam Capital; GV20 Oncotherapy, a  Cambridge ,  MA - Shanghai  biotech, completed a Series B round to advance its lead immuno-oncology antibody candidate into the clinic; Eucure Bio, a subsidiary of  Beijing 's Biocytogen, will collaborate with Tracon Pharma to develop its CTLA-4 antibody for soft tissue sarcoma in  North America ;   Company News   Bristol-Myers wants to dissolve its $1.4 billion deal with  Beijing 's BeiGene  because China has stopped distribution of Abraxane due to a manufacturing issue; AnchorDx of Guangzhou and South San Francisco 's Twist Bioscience launched their Pan-Cancer Methylation Panel in global markets; Shanghai Zai Lab will collaborate with Geneseeq, a Toronto-China company, to integrate new NGS services into clinical trials and advance precision care;  Trials and Approvals   Sirtex Medical, a division of China Grand Pharma and Healthcare, started a  China  trial of its selective internal radiation therapy in patients with liver cancer; Suzhou Kintor Pharma (HK: 9939) was approved to start a China Phase I combination trial of its ALK-1 antibody and a PD-1, also in liver cancer.  Stock Symbols: (HK: 3692) (KOSDAQ: 226950) (HK: 2256) (NSDQ: STRO) (NSDQ: TCON) (NYSE: BMY) (NSDQ: BGNE; HK: 6160) (NSDQ: TWST) (NSDQ: ZLAB; HK: 9688) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.